Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSCT ALL/MRD2023 treatment protocol for adult acute lymphoblastic leukemia
jRCTs071220071Recruiting
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of blinatumomab, dasatinib, ponatinib and prednisolone in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL) (3 arms). Primary endpoint: 3-year disease-free survival rate. Started Jan 2023; status: recruiting.
02
Drugs
blinatumomabdasatinibponatinibprednisolone
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on jRCTs071220071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220071.